Atyr Pharma Stock Performance
| ATYR Stock | 0.88 0.08 8.33% |
On a scale of 0 to 100, ATyr Pharma holds a performance score of 3. The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ATyr Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding ATyr Pharma is expected to be smaller as well. Please check ATyr Pharma's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether ATyr Pharma's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in aTyr Pharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively conflicting basic indicators, ATyr Pharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:14 | Last Split Date 2019-07-01 |
1 | Bragar Eagel Squire, P.C. Reminds Stockholders of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights Before Upcoming Deadlines | 11/17/2025 |
2 | Lost Money on aTyr Pharma, Inc. Join Class Action Suit Seeking Recovery Contact Levi Korsinsky | 12/01/2025 |
3 | aTyr Pharma, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights - ATYR | 12/04/2025 |
4 | aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ATYR | 12/05/2025 |
5 | Shareholders that lost money on aTyr Pharma, Inc. Urged to Join Class Action Contact The Gross Law Firm to Learn More | 12/08/2025 |
6 | ATYR Deadline ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit | 12/09/2025 |
7 | Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. Shareholders | 12/15/2025 |
8 | aTyr Pharma, Inc. Stock Analysis Unveiling a 483 percent Potential Upside in Biotech Innovation - DirectorsTalk Interviews | 01/08/2026 |
9 | Acquisition by Denyes Nancy of 412500 shares of ATyr Pharma at 0.7127 subject to Rule 16b-3 | 01/09/2026 |
10 | aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis | 02/03/2026 |
| Begin Period Cash Flow | 26 M | |
| Total Cashflows From Investing Activities | 17.2 M | |
| Free Cash Flow | -69.2 M |
ATyr Pharma Relative Risk vs. Return Landscape
If you would invest 82.00 in aTyr Pharma on November 7, 2025 and sell it today you would earn a total of 6.00 from holding aTyr Pharma or generate 7.32% return on investment over 90 days. aTyr Pharma is currently generating 0.272% in daily expected returns and assumes 5.789% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than ATyr, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ATyr Pharma Target Price Odds to finish over Current Price
The tendency of ATyr Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.88 | 90 days | 0.88 | under 4 |
Based on a normal probability distribution, the odds of ATyr Pharma to move above the current price in 90 days from now is under 4 (This aTyr Pharma probability density function shows the probability of ATyr Stock to fall within a particular range of prices over 90 days) .
ATyr Pharma Price Density |
| Price |
Predictive Modules for ATyr Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as aTyr Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ATyr Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ATyr Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ATyr Pharma is not an exception. The market had few large corrections towards the ATyr Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold aTyr Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ATyr Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.10 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 0.07 | |
Ir | Information ratio | 0.01 |
ATyr Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ATyr Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for aTyr Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| aTyr Pharma had very high historical volatility over the last 90 days | |
| aTyr Pharma has some characteristics of a very speculative penny stock | |
| aTyr Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 235 K. Net Loss for the year was (64.02 M) with loss before overhead, payroll, taxes, and interest of (61.37 M). | |
| ATyr Pharma generates negative cash flow from operations | |
| aTyr Pharma has a poor financial position based on the latest SEC disclosures | |
| About 60.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis |
ATyr Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ATyr Stock often depends not only on the future outlook of the current and potential ATyr Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ATyr Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 74.3 M | |
| Cash And Short Term Investments | 72.1 M |
ATyr Pharma Fundamentals Growth
ATyr Stock prices reflect investors' perceptions of the future prospects and financial health of ATyr Pharma, and ATyr Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ATyr Stock performance.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (140.76) % | ||||
| Current Valuation | 17.22 M | ||||
| Shares Outstanding | 97.99 M | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 495.19 X | ||||
| Revenue | 235 K | ||||
| Gross Profit | (61.37 M) | ||||
| EBITDA | (66.37 M) | ||||
| Net Income | (64.02 M) | ||||
| Total Debt | 13.28 M | ||||
| Book Value Per Share | 0.82 X | ||||
| Cash Flow From Operations | (69.12 M) | ||||
| Earnings Per Share | (0.83) X | ||||
| Market Capitalization | 94.09 M | ||||
| Total Asset | 96.83 M | ||||
| Retained Earnings | (532.05 M) | ||||
| Working Capital | 66.99 M | ||||
About ATyr Pharma Performance
Assessing ATyr Pharma's fundamental ratios provides investors with valuable insights into ATyr Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ATyr Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.62) | |
| Return On Capital Employed | (0.75) | (0.78) | |
| Return On Assets | (0.60) | (0.62) | |
| Return On Equity | (1.05) | (1.00) |
Things to note about aTyr Pharma performance evaluation
Checking the ongoing alerts about ATyr Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for aTyr Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| aTyr Pharma had very high historical volatility over the last 90 days | |
| aTyr Pharma has some characteristics of a very speculative penny stock | |
| aTyr Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 235 K. Net Loss for the year was (64.02 M) with loss before overhead, payroll, taxes, and interest of (61.37 M). | |
| ATyr Pharma generates negative cash flow from operations | |
| aTyr Pharma has a poor financial position based on the latest SEC disclosures | |
| About 60.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis |
- Analyzing ATyr Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ATyr Pharma's stock is overvalued or undervalued compared to its peers.
- Examining ATyr Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ATyr Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ATyr Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ATyr Pharma's stock. These opinions can provide insight into ATyr Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.